{"id":"https://openalex.org/W3095745170","doi":"https://doi.org/10.1182/blood-2020-137630","title":"Phase I Dose-Escalation Trial of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia","display_name":"Phase I Dose-Escalation Trial of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia","publication_year":2020,"publication_date":"2020-11-05","ids":{"openalex":"https://openalex.org/W3095745170","doi":"https://doi.org/10.1182/blood-2020-137630","mag":"3095745170"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-137630","doi":"https://doi.org/10.1182/blood-2020-137630","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-137630","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067146863","display_name":"Sanaz Noelle Ghafouri","orcid":"https://orcid.org/0000-0002-1610-220X","observed_orcids":["https://orcid.org/0000-0002-1610-220X"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sanaz Ghafouri","raw_affiliation_strings":["Department of Hematology and Oncology, University of California Los Angeles, Saratoga, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology and Oncology, University of California Los Angeles, Saratoga, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035989752","display_name":"Christopher M. Walthers","orcid":"https://orcid.org/0000-0002-8760-7870","observed_orcids":["https://orcid.org/0000-0002-8760-7870"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher Walthers","raw_affiliation_strings":["UCLA, los angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA, los angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017311672","display_name":"Mobina Roshandell","orcid":"https://orcid.org/0000-0002-7073-6617","observed_orcids":["https://orcid.org/0000-0002-7073-6617"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mobina Roshandell","raw_affiliation_strings":["UCLA, los angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA, los angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041661955","display_name":"Brenda Ji","orcid":"https://orcid.org/0000-0002-9357-1616","observed_orcids":["https://orcid.org/0000-0002-9357-1616"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brenda Ji","raw_affiliation_strings":["UCLA, los angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA, los angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029446022","display_name":"Jacqueline Trent","orcid":"https://orcid.org/0000-0002-3726-4646","observed_orcids":["https://orcid.org/0000-0002-3726-4646"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacqueline Trent","raw_affiliation_strings":["UCLA, los angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA, los angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053234229","display_name":"Jia Ming Chen","orcid":"https://orcid.org/0000-0003-3992-9143","observed_orcids":["https://orcid.org/0000-0003-3992-9143"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jia Ming Chen","raw_affiliation_strings":["UCLA, los angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA, los angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009397882","display_name":"Jacob Naparstek","orcid":"https://orcid.org/0000-0002-2047-4532","observed_orcids":["https://orcid.org/0000-0002-2047-4532"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacob Naparstek","raw_affiliation_strings":["UCLA, los angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA, los angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078705613","display_name":"Monica Diane Mead","orcid":"https://orcid.org/0000-0001-9175-0189","observed_orcids":["https://orcid.org/0000-0001-9175-0189"]},"institutions":[{"id":"https://openalex.org/I2801403999","display_name":"UCLA Medical Center","ror":"https://ror.org/04vq5kb54","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I2801403999"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Monica Mead","raw_affiliation_strings":["Department of Hematology/Oncology, UCLA Medical Center, Santa Monica, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology/Oncology, UCLA Medical Center, Santa Monica, CA","institution_ids":["https://openalex.org/I2801403999"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107833759","display_name":"John M. Timmerman","orcid":"https://orcid.org/0000-0003-4104-8943","observed_orcids":["https://orcid.org/0000-0003-4104-8943"]},"institutions":[{"id":"https://openalex.org/I2801272649","display_name":"Ronald Reagan UCLA Medical Center","ror":"https://ror.org/04k3jt835","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I2801272649"]},{"id":"https://openalex.org/I2801403999","display_name":"UCLA Medical Center","ror":"https://ror.org/04vq5kb54","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I2801403999"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John M. Timmerman","raw_affiliation_strings":["Division of Hematology & Oncology, UCLA Medical Center, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology & Oncology, UCLA Medical Center, Los Angeles, CA","institution_ids":["https://openalex.org/I2801272649","https://openalex.org/I2801403999"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056297995","display_name":"Yvonne Chen","orcid":"https://orcid.org/0000-0001-8844-7891","observed_orcids":["https://orcid.org/0000-0001-8844-7891","https://orcid.org/0000-0003-4755-6025"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yvonne Chen","raw_affiliation_strings":["University of California Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5041161932","display_name":"Sarah Marie Larson","orcid":"https://orcid.org/0000-0002-4335-2925","observed_orcids":["https://orcid.org/0000-0002-4335-2925"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah Larson","raw_affiliation_strings":["UCLA, Santa Monica, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA, Santa Monica, CA","institution_ids":["https://openalex.org/I161318765"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.4516,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":{"value":0.63283667,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"136","issue":"Supplement 1","first_page":"19","last_page":"20"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chimeric-antigen-receptor","display_name":"chimeric antigen receptor","score":0.8220000267028809},{"id":"https://openalex.org/keywords/relapsed-or-refractory-b-cell-lymphoma","display_name":"relapsed or refractory B-cell lymphoma","score":0.9100000262260437},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9929999709129333},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.902999997138977},{"id":"https://openalex.org/keywords/primary-mediastinal-large-b-cell-lymphoma","display_name":"primary mediastinal B-cell lymphoma","score":0.9670000076293945},{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.9919999837875366},{"id":"https://openalex.org/keywords/follicular-lymphoma","display_name":"follicular lymphoma","score":0.984000027179718},{"id":"https://openalex.org/keywords/small-lymphocytic-leukemia","display_name":"small lymphocytic leukemia","score":0.925000011920929},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7670000195503235},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.75},{"id":"https://openalex.org/keywords/lymphodepleting-chemotherapy","display_name":"lymphodepleting chemotherapy","score":0.7870000004768372},{"id":"https://openalex.org/keywords/fludarabine-and-cyclophosphamide","display_name":"fludarabine and cyclophosphamide","score":0.8899999856948853},{"id":"https://openalex.org/keywords/lentiviral-transduction","display_name":"lentiviral transduction","score":0.5630000233650208}],"concepts":[{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.7536237239837646},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7182594537734985},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.7051600217819214},{"id":"https://openalex.org/C18031839","wikidata":"https://www.wikidata.org/wiki/Q5009796","display_name":"CD20","level":3,"score":0.5924464464187622},{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.5724833011627197},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5013031959533691},{"id":"https://openalex.org/C2777058707","wikidata":"https://www.wikidata.org/wiki/Q123251","display_name":"Follicular lymphoma","level":3,"score":0.4727666676044464},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.47127765417099},{"id":"https://openalex.org/C2778957590","wikidata":"https://www.wikidata.org/wiki/Q798033","display_name":"CD19","level":3,"score":0.44125375151634216},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4080261290073395},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.40418750047683716},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3793206810951233},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.377602756023407},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3602430820465088},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.3550650477409363},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.3136342763900757},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2758204936981201},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2692008316516876},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2107226848602295}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-137630","doi":"https://doi.org/10.1182/blood-2020-137630","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-137630","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3177687441","https://openalex.org/W4365514034","https://openalex.org/W2947160894","https://openalex.org/W4286296861","https://openalex.org/W4389220851","https://openalex.org/W4417008360","https://openalex.org/W3089727781","https://openalex.org/W4417005975","https://openalex.org/W4309797052","https://openalex.org/W7108463192"],"abstract_inverted_index":{"Background:":[0],"Single-input":[1],"anti-CD19":[2,74],"CAR":[3,31,42,81,162,166,215,251,318,335,365,370],"T-cells":[4,43,83,216],"have":[5,103],"demonstrated":[6],"clinical":[7,89,435],"efficacy":[8],"for":[9,91,111,129,156,217],"relapsed":[10],"or":[11,524,536],"refractory":[12],"(R/R)":[13],"non-Hodgkin":[14],"B-cell":[15,114,120,339],"lymphoma":[16,115,121,132,135],"(NHL)":[17],"and":[18,51,69,117,123,138,152,221,231,253,264,289,338,343,377,384,386,403,422,433,436],"chronic":[19],"lymphocytic":[20,140],"leukemia":[21,141],"(CLL).":[22],"Despite":[23],"excellent":[24],"response":[25],"rates,":[26],"over":[27],"50%":[28],"of":[29,39,72,109,127,188,227,234,300,328,356,399,417,425,522,534],"CD19":[30],"T-cell":[32,163,167,336,366,371],"recipients":[33],"relapse.":[34],"Preclinical":[35],"data":[36,438],"show":[37],"engineering":[38],"bispecific":[40,79],"anti-CD19/CD20":[41,80,161],"via":[44],"lentiviral":[45],"transduction":[46],"effectively":[47],"targets":[48],"tumor":[49],"cells":[50,197,421],"overcomes":[52],"antigen":[53,393,401],"escape":[54],"(Zah":[55],"E":[56],"et":[57],"al.,":[58],"Cancer":[59],"Immunol":[60],"Res,":[61],"2016).":[62],"Based":[63],"on":[64,207,246,274,442,518,530],"these":[65],"promising":[66],"preclinical":[67],"results":[68],"the":[70,78,179,295,301,329,360,388,391,415,423,443],"limitations":[71],"single-input":[73],"CARs,":[75],"we":[76,350],"investigated":[77],"na\u00efve/memory":[82,419],"in":[84,305,354,379,453,461,469,508,551],"a":[85,185,232,495],"phase":[86],"I":[87],"dose-escalation":[88],"trial":[90,99,428],"patients":[92,101,204,303,358,380,432],"with":[93,148,172,184,210,223,325,381,390],"R/R":[94,218,382],"NHL/CLL":[95],"(NCT04007029).":[96],"Methods:":[97],"This":[98],"includes":[100],"who":[102],"measurable":[104],"disease":[105,314],"after":[106,124,317,323],"2":[107,299,355],"lines":[108,126],"therapy":[110,128,372],"diffuse":[112],"large":[113],"(DLBCL)":[116],"primary":[118],"mediastinal":[119],"(PMBCL),":[122],"3":[125,241,255,302,357],"mantle":[130],"cell":[131],"(MCL),":[133],"follicular":[134],"(FL),":[136],"CLL":[137,385],"small":[139],"(SLL).":[142],"Eligible":[143],"participants":[144],"received":[145,205,256],"lymphodepleting":[146],"chemotherapy":[147],"fludarabine":[149],"30":[150],"mg/m2":[151,155],"cyclophosphamide":[153],"500":[154],"three":[157,203],"days,":[158],"followed":[159],"by":[160,341,396],"infusion.":[164],"The":[165,259,283,427],"infusion":[168,252,260,267],"will":[169],"be":[170,375],"given":[171],"standard":[173],"\"3+3\"":[174],"dose":[175,182,186,278],"escalation":[176],"to":[177,192,250,332,374,413,430],"determine":[178,414],"maximum":[180,284],"tolerated":[181,263],"(MTD),":[183],"range":[187],"5":[189,211,361],"x":[190,194,212,362],"107":[191,213,363],"6":[193],"108":[195],"CAR-positive":[196],"per":[198],"patient.":[199],"Results:":[200],"To":[201],"date,":[202,298],"treatment":[206,324],"cohort":[208],"1":[209,288],"CD19/CD20":[214,364,369],"MCL,":[219],"FL":[220],"PMBCL,":[222],"an":[224,519,531],"average":[225],"age":[226],"49.3":[228],"(range,":[229,238],"29-60)":[230],"mean":[233],"3.7":[235],"prior":[236,249],"regimens":[237],"3-4).":[239],"All":[240],"patients'":[242],"lymphomas":[243],"were":[244,281],"CD19+/CD20+":[245],"tissue":[247],"biopsy":[248],"all":[254],"bridging":[257],"chemotherapy.":[258],"was":[261,272,287,291],"well":[262],"no":[265,292],"major":[266],"reactions":[268],"occurred.":[269],"Peak":[270],"expansion":[271],"noted":[273],"day":[275],"14.":[276],"No":[277],"limiting":[279],"toxicities":[280],"identified.":[282],"grade":[285],"CRS":[286],"there":[290],"ICANS.":[293],"At":[294],"6.0-month":[296,344],"cutoff":[297],"remain":[304],"ongoing":[306,334],"complete":[307],"remission.":[308],"Unfortunately,":[309],"one":[310],"patient":[311,445],"developed":[312],"progressive":[313],"0.5":[315],"months":[316],"infusion,":[319],"yet":[320],"remains":[321],"alive":[322],"immunotherapy.":[326],"Both":[327],"responders":[330],"continue":[331],"demonstrate":[333,351],"persistence":[337],"aplasia":[340],"3.0":[342],"follow":[345,408],"up,":[346],"respectively.":[347],"Conclusions:":[348],"Here":[349],"impressive":[352],"responses":[353],"at":[359],"dosages.":[367],"Bispecific":[368],"appears":[373],"safe":[376],"effective":[378],"NHL":[383],"obviates":[387],"challenges":[389],"single":[392],"directed":[394],"CARs":[395],"decreasing":[397],"risk":[398],"target":[400],"loss":[402],"expression":[404],"downregulation.":[405],"A":[406],"longer":[407],"up":[409],"period":[410],"is":[411],"required":[412],"impact":[416],"modifying":[418],"T":[420],"durability":[424],"response.":[426],"continues":[429],"enroll":[431],"additional":[434],"translational":[437],"are":[439],"being":[440],"collected":[441],"initial":[444],"cohort.":[446],"Disclosures":[447],"Timmerman:":[448],"Corvus:":[449],"Current":[450,458,466,505,548],"equity":[451,459,467,506,549],"holder":[452,460,468,507,550],"publicly-traded":[454,462,470,509],"company;":[455,463,471],"Marker":[456],"Therapeutics:":[457,476,512,516],"Bluebird":[464],"Bio:":[465],"Immune":[472],"Design:":[473],"Honoraria;":[474],"Celldex":[475],"Consultancy;":[477],"Valor:":[478],"Research":[479,482,486,492,502,544],"Funding;":[480,483,487,493,503,545],"Merck:":[481],"Spectrum":[484],"Pharmaceuticals:":[485],"BMS:":[488],"Other:":[489,499,513],"Travel":[490,500],"support,":[491,501],"Kite,":[494],"Gilead":[496],"Company:":[497],"Consultancy,":[498],"Genmab:":[504],"company.":[510,553],"Chen:Kalthera":[511],"Co-founder;":[514],"Notch":[515],"Membership":[517,529],"entity's":[520,532],"Board":[521,533],"Directors":[523,535],"advisory":[525,537],"committees;":[526],"Gritstone":[527],"Oncology:":[528],"committees.":[538],"Larson:BMS,":[539],"Bioline,":[540],"Celgene,":[541],"Juno,":[542],"Janssen:":[543],"TORL":[546],"Biotherapeutics:":[547],"private":[552]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":4}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2020-11-09T00:00:00"}